Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gossamer Bio (GOSS), High Tide (HITI) and Arvinas Holding Company (ARVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gossamer Bio (GOSS), High Tide (HITI) and Arvinas Holding Company (ARVN).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gossamer Bio (GOSS)
Wedbush analyst Laura Chico maintained a Hold rating on Gossamer Bio today and set a price target of $1.00. The company’s shares closed last Wednesday at $0.43.
According to TipRanks.com, Chico is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Gossamer Bio with a $3.69 average price target, implying a 706.6% upside from current levels. In a report issued on March 17, TipRanks – xAI also reiterated a Hold rating on the stock with a $0.45 price target.
See today’s best-performing stocks on TipRanks >>
High Tide (HITI)
In a report released today, Frederico Gomes from ATB Cormark Capital Markets maintained a Buy rating on High Tide, with a price target of C$7.00. The company’s shares closed last Wednesday at $2.45.
According to TipRanks.com, Gomes is a 1-star analyst with an average return of
High Tide has an analyst consensus of Strong Buy, with a price target consensus of $5.15, representing a 90.7% upside. In a report released yesterday, Haywood also maintained a Buy rating on the stock with a C$8.00 price target.
Arvinas Holding Company (ARVN)
In a report released today, Robert Driscoll from Wedbush reiterated a Hold rating on Arvinas Holding Company, with a price target of $11.00. The company’s shares closed last Wednesday at $10.89, close to its 52-week low of $7.53.
According to TipRanks.com, Driscoll is a 4-star analyst with an average return of
Currently, the analyst consensus on Arvinas Holding Company is a Moderate Buy with an average price target of $16.45, implying a 39.1% upside from current levels. In a report issued on March 17, Truist Financial also maintained a Hold rating on the stock.
Read More on GOSS:
Disclaimer & DisclosureReport an Issue
- Gossamer Bio’s Seralutinib Future in Doubt After PROSERA Miss in PAH Raises FDA, Funding and Viability Risks
- Gossamer Bio reports Q4 EPS (21c), consensus (20c)
- Stagflation Risk Is Back — These 3 Stocks Can Help Defend Your Portfolio
- Gossamer Bio options imply 46.1% move in share price post-earnings
- GOSS Upcoming Earnings Report: What to Expect?
